"The most bizarre we've ever seen." That's how Jefferies & Co. analyst Corey Davis described the FDA advisory panel meeting earlier this month on Daxas (roflumilast), the drug candidate for chronic obstructive pulmonary disease from Forest Laboratories Inc. and Nycomed GmbH. Read More
